Glaxo to Shell £1.6bn to Solve its Legal Woes

GlaxoSmithKline, the famous drugs giant, yesterday announced that it extended an estimated £1.57bn worth charge in a view to reconcile a string of disputes over its controversial Avandia diabetes treatment and other drugs, witnessed in the second quarter.

Europe's biggest pharmaceutical Company has been facing a series of longstanding woes including charges that has linked its diabetic drug Avandia to cardiovascular problem.

In addition, the Company posted that the second-quarter charge requires addressing a string of liability cases relating to its Paxil anti-depressant drug, as well.

Moreover, belittling claims related to its Apotex, claiming it to generic version of GSK's Paxil treatment, has also been placated and is reveled to be included in the charge.

“The charge we have announced today reflects the company's ongoing efforts to resolve certain long-standing legal cases”, posited, GSK General Counsel, Dan Troy.

The European Medicines Agency is scheduled to table in order to take a decision on whether to allow Avandia to be officially retailed in the European markets.

However, GSK would not disturb the £1.57billion charge, except its £500million concerning its Cidra plant.

“The last two days look to have been good for Glaxo, helping to draw a line under various disputes, at least as far as you can in these situations”, quoted, Jonathan Jackson, Head of Equities at Brokerage Killik & Co.

Companies: